Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Sells $37,058.64 in Stock

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) major shareholder Matt Davidson sold 3,516 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $10.54, for a total value of $37,058.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Matt Davidson also recently made the following trade(s):

  • On Friday, May 10th, Matt Davidson sold 3,356 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.21, for a total value of $30,908.76.
  • On Tuesday, May 7th, Matt Davidson sold 3,900 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.28, for a total value of $36,192.00.
  • On Thursday, May 2nd, Matt Davidson sold 1,768 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.86, for a total value of $17,432.48.
  • On Monday, April 29th, Matt Davidson sold 3,302 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.90, for a total value of $32,689.80.
  • On Wednesday, April 24th, Matt Davidson sold 9,203 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $9.92, for a total value of $91,293.76.
  • On Tuesday, April 16th, Matt Davidson sold 3,193 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.39, for a total value of $33,175.27.
  • On Thursday, April 11th, Matt Davidson sold 18,850 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.16, for a total value of $191,516.00.
  • On Monday, April 8th, Matt Davidson sold 12,385 shares of Verrica Pharmaceuticals stock. The shares were sold at an average price of $10.67, for a total value of $132,147.95.
  • On Wednesday, April 3rd, Matt Davidson sold 13,436 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $10.37, for a total value of $139,331.32.
  • On Tuesday, March 26th, Matt Davidson sold 13,667 shares of Verrica Pharmaceuticals stock. The stock was sold at an average price of $11.50, for a total value of $157,170.50.

Shares of NASDAQ VRCA traded down $0.27 during mid-day trading on Friday, hitting $9.10. The company had a trading volume of 18,777 shares, compared to its average volume of 29,232. The stock has a market cap of $240.89 million and a PE ratio of -6.45. Verrica Pharmaceuticals Inc has a 1 year low of $6.44 and a 1 year high of $23.29.

Verrica Pharmaceuticals (NASDAQ:VRCA) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.02). Analysts predict that Verrica Pharmaceuticals Inc will post -1.18 EPS for the current fiscal year.

A number of analysts have issued reports on the company. HC Wainwright assumed coverage on Verrica Pharmaceuticals in a research report on Thursday, February 21st. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research downgraded Verrica Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Verrica Pharmaceuticals has an average rating of “Buy” and an average target price of $26.25.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Capital Investment Advisory Services LLC grew its position in shares of Verrica Pharmaceuticals by 15.9% in the fourth quarter. Capital Investment Advisory Services LLC now owns 12,400 shares of the company’s stock valued at $101,000 after purchasing an additional 1,700 shares in the last quarter. American International Group Inc. boosted its stake in Verrica Pharmaceuticals by 79.6% during the first quarter. American International Group Inc. now owns 6,861 shares of the company’s stock valued at $74,000 after buying an additional 3,040 shares during the period. New York State Common Retirement Fund bought a new stake in Verrica Pharmaceuticals during the fourth quarter valued at $28,000. Bank of New York Mellon Corp boosted its stake in Verrica Pharmaceuticals by 39.1% during the fourth quarter. Bank of New York Mellon Corp now owns 16,662 shares of the company’s stock valued at $136,000 after buying an additional 4,681 shares during the period. Finally, Northern Trust Corp boosted its stake in Verrica Pharmaceuticals by 7.5% during the fourth quarter. Northern Trust Corp now owns 67,028 shares of the company’s stock valued at $546,000 after buying an additional 4,689 shares during the period. Institutional investors own 32.87% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Verrica Pharmaceuticals Inc (VRCA) Major Shareholder Sells $37,058.64 in Stock” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.baseballdailydigest.com/news/2019/05/11/verrica-pharmaceuticals-inc-vrca-major-shareholder-matt-davidson-sells-3516-shares-of-stock.html.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts.

Read More: Stock Symbol

Insider Buying and Selling by Quarter for Verrica Pharmaceuticals (NASDAQ:VRCA)

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.